Results 41 to 50 of about 79,111 (213)

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. [PDF]

, 2019
BACKGROUND: Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
Andersson, B, Anker, SD, Beta-Blockers in Heart Failure Collaborative Group, Böhm, M, Cleland, JGF, Coats, AJS, Damman, K, Flather, MD, Gill, SK, Holmes, J, Kjekshus, J, Kotecha, D, Manzano, L, McMurray, JJV, Packer, M, Redon, J, Rigby, AS, Rosano, G, Ruschitzka, F, van Veldhuisen, DJ, von Lueder, TG, Wedel, H, Wikstrand, J   +22 more
core   +8 more sources

Combined Angiotensin II Type-1 Receptor Blockade and Superoxide Anion Scavenging Affect the Post-Ischemic Kidney in Hypertensive Rats

Acta Veterinaria, 2016
Ischemic acute kidney injury is characterized by renal vasoconstriction, filtration failure, tubular obstruction, tubular backleak and overproduction of angiotensin II and reactive oxygen species.
Ivanov Milan, Mihailović-Stanojević Nevena, Marković-Lipkovski Jasmina, Jovović Đurđica, Karanović Danijela, Miloradović Zoran, Grujić-Milanović Jelica   +6 more
doaj   +1 more source

What is the best treatment for hypertension in African Americans? [PDF]

, 2007
In African Americans with hypertension, therapy is best initiated with the low-sodium Dietary Approaches to Stop Hypertension (DASH) diet and a thiazide-type diuretic (strength of recommendation [SOR]: A, based on randomized controlled trials).
Cherukuri, Manjula, Mayo, Helen G., Rao, Shobha   +2 more
core  

Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: the design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial [PDF]

, 2017
Background: Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure.
Braunwald, Eugene, Cirino, Allison L., Colan, Steven D., Day, Sharlene M., Desai, Akshay S., Ho, Carolyn Y., Lipshultz, Steven E., MacRae, Calum A., McMurray, John J.V., Orav, E. John, Shi, Ling, Solomon, Scott D.   +11 more
core   +1 more source

Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [PDF]

, 2017
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those with lower SBP have a worse prognosis. To make matters worse, the latter patients often do not receive treatment with life-saving therapies that might ...
Böhm, Michael, Gong, Jianjian, Jhund, Pardeep, Lefkowitz, Martin P., McMurray, John J.V., Packer, Milton, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Swedberg, Karl, Young, Robin, Zile, Michael R.   +12 more
core   +1 more source

Angiotensin III/AT2 Receptor/NHE3 Signaling Pathway in the Proximal Tubules of the Kidney: A Novel Natriuretic and Antihypertensive Mechanism in Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
See Article Kemp et ...
Jia L. Zhuo, Xiao C. Li
doaj   +1 more source

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. [PDF]

, 2018
Background Our objective was to determine patterns of antihypertensive agent use by stage of chronic kidney disease (CKD) and to evaluate the association between different classes of antihypertensive agents with nonrenal outcomes, especially in advanced ...
Johansen, Kirsten L, Ku, Elaine, Lin, Feng, McCulloch, Charles E, Vittinghoff, Eric   +4 more
core  

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome [PDF]

, 2008
Background: Progressive enlargement of the aortic root, leading to dissection, is the main cause of premature death in patients with Marfan's syndrome. Recent data from mouse models of Marfan's syndrome suggest that aortic-root enlargement is caused by ...
Brooke, Benjamin S., Dietz, Harry C., Habashi, Jennifer P., Judge, Daniel P., Loeys, Bart, Patel, Nishant   +5 more
core   +2 more sources

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

Clinical pharmacogenetics of angiotensin II receptor blockers

Pharmacogenetics and Pharmacogenomics, 2020
This scientific review presents a current data on the effect of genetic polymorphism of CYP2C9 genes and genes encoding components of the renin-angiotensin-aldosterone system (RAAS) on the angiotensin II receptor blockers (ARBs) pharmacokinetics and pharmacodynamics.
I. I. Sinitsina, A. V. Boyarko, I. I. Temirbulatov   +2 more
openaire   +2 more sources